## CLAIMS

1. An isolated human antibody capable of recognizing and binding to an epitope in the HA2 subunit of the influenza haemagglutinin protein (HA), characterized in that said binding molecule has neutralizing activity against an influenza virus comprising HA of the H5 subtype and wherein said antibody also has neutralizing activity against an influenza virus comprising HA of the H1 subtype, wherein the antibody comprises a heavy chain CDR1 region of SEQ ID NO:1, a heavy chain CDR2 region of SEQ ID NO:2, a heavy chain CDR3 region of SEQ ID NO:3, a light chain CDR1 region of SEQ ID NO:13, a light chain CDR2 region of SEQ ID NO:14, and a light chain CDR3 region of SEQ ID NO:15.
2. An antibody according to claim 1, wherein the antibody comprises a heavy chain variable region comprising the amino acids 1-121 of SEQ ID NO: 65, and a light chain variable region comprising the amino acids 1-112 of SEQ ID NO: 91.
3. A nucleic acid molecule encoding an antibody according to claim 1 or 2.
4. An antibody according to claim 1 or 2 for use as a medicament and preferably for the diagnostic, therapeutic and/or prophylactic treatment of influenza infection.
5. An antibody according to claim 4, wherein said influenza infection is caused by an influenza virus that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak.
6. An antibody according to claim 5, wherein said influenza virus strain that is associated with a pandemic outbreak is selected from the group consisting of: H1N1, H5N1, H5N2, H5N8, H5N9, an H2-based strain, and H9N2.

7. A pharmaceutical composition comprising an antibody according to any of the claims 1-6, and a pharmaceutically acceptable excipient.
8. Use of an antibody according to any of the claims 1-6 in the preparation of a medicament for the diagnosis, prophylaxis, and/or treatment of an influenza virus infection, wherein the influenza infection is caused by an influenza virus of the H1 and/or H5 subtype.